Carl Zeiss Meditec
Market Cap
€8.4b
Last Updated
2020/07/07 20:50 UTC
Data Sources
Company Financials +
Executive Summary
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally.
Rewards
PE ratio (50.1x) is below the Medical Equipment industry average (53x)
Risk Analysis
No risks detected for AFX from our risk checks.
Snowflake Analysis
Flawless balance sheet with solid track record.
Similar Companies
Share Price & News
How has Carl Zeiss Meditec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AFX has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
6.6%
AFX
0.9%
DE Medical Equipment
2.1%
DE Market
1 Year Return
7.3%
AFX
20.3%
DE Medical Equipment
2.1%
DE Market
Return vs Industry: AFX underperformed the German Medical Equipment industry which returned 20.4% over the past year.
Return vs Market: AFX exceeded the German Market which returned 3% over the past year.
Shareholder returns
| AFX | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.6% | 0.9% | 2.1% |
| 30 Day | -0.7% | -2.8% | -0.8% |
| 90 Day | 0.3% | 15.1% | 20.1% |
| 1 Year | 7.3%7.3% | 21.8%20.3% | 4.2%2.1% |
| 3 Year | 113.0%109.3% | 121.8%117.1% | 3.7%-4.7% |
| 5 Year | 291.9%276.6% | 248.4%234.4% | 10.7%-4.0% |
Price Volatility Vs. Market
How volatile is Carl Zeiss Meditec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
The Returns At Carl Zeiss Meditec (ETR:AFX) Provide Us With Signs Of What's To Come4 weeks ago | Simply Wall St
Does Carl Zeiss Meditec AG's (ETR:AFX) CEO Pay Matter?1 month ago | Simply Wall St
Carl Zeiss Meditec AG's (ETR:AFX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?Valuation
Is Carl Zeiss Meditec undervalued compared to its fair value and its price relative to the market?
50.15x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: AFX (€92.5) is trading above our estimate of fair value (€61.38)
Significantly Below Fair Value: AFX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: AFX is good value based on its PE Ratio (50.1x) compared to the Medical Equipment industry average (53x).
PE vs Market: AFX is poor value based on its PE Ratio (50.1x) compared to the German market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: AFX is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: AFX is overvalued based on its PB Ratio (5.7x) compared to the DE Medical Equipment industry average (4.5x).
Next Steps
Future Growth
How is Carl Zeiss Meditec forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
14.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFX's forecast earnings growth (14.7% per year) is above the savings rate (0.2%).
Earnings vs Market: AFX's earnings (14.7% per year) are forecast to grow slower than the German market (22.4% per year).
High Growth Earnings: AFX's earnings are forecast to grow, but not significantly.
Revenue vs Market: AFX's revenue (8.1% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: AFX's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AFX's Return on Equity is forecast to be low in 3 years time (14%).
Next Steps
Past Performance
How has Carl Zeiss Meditec performed over the past 5 years?
18.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AFX has high quality earnings.
Growing Profit Margin: AFX's current net profit margins (11%) are higher than last year (9.6%).
Past Earnings Growth Analysis
Earnings Trend: AFX's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: AFX's earnings growth over the past year (28.6%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: AFX earnings growth over the past year (28.6%) exceeded the Medical Equipment industry 8.2%.
Return on Equity
High ROE: AFX's Return on Equity (11.3%) is considered low.
Next Steps
Financial Health
How is Carl Zeiss Meditec's financial position?
Financial Position Analysis
Short Term Liabilities: AFX's short term assets (€1.4B) exceed its short term liabilities (€335.4M).
Long Term Liabilities: AFX's short term assets (€1.4B) exceed its long term liabilities (€265.7M).
Debt to Equity History and Analysis
Debt Level: AFX is debt free.
Reducing Debt: AFX has no debt compared to 5 years ago when its debt to equity ratio was 0.6%.
Debt Coverage: AFX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AFX has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Carl Zeiss Meditec current dividend yield, its reliability and sustainability?
0.70%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: AFX's dividend (0.7%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).
High Dividend: AFX's dividend (0.7%) is low compared to the top 25% of dividend payers in the German market (3.8%).
Stability and Growth of Payments
Stable Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: AFX is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: AFX is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AFX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.8yrs
Average management tenure
CEO
Ludwin Monz (57yo)
10.33yrs
Tenure
€1,853,900
Compensation
Dr. Ludwin Monz, Ph.D., M.B.A. has been the Chairman of Management Board at Carl Zeiss Meditec AG since October 8, 2007. Dr. Monz has been the Chief Executive Officer and President of Carl Zeiss Meditec AG ...
CEO Compensation Analysis
Compensation vs Market: Ludwin's total compensation ($USD2.09M) is below average for companies of similar size in the German market ($USD3.54M).
Compensation vs Earnings: Ludwin's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.33yrs | €1.85m | no data | |
| CFO & Member of the Management Board | 1.75yrs | €855.50k | no data | |
| Head of Surgical Ophthalmology & Member of Management Board | 1.75yrs | €921.70k | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Head of the Planetarium Business Unit | no data | no data | no data | |
| Head of Marketing - Shanghai | no data | no data | no data | |
| Chief Medical Officer for Global Ophthalmic Devices | 3.75yrs | no data | no data | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | no data | no data | no data | |
| Head of Global Communications Ophthalmic Devices | no data | no data | no data | |
| President of Ophthalmic Devices & Head of the Ophthalmic Devices Strategic Business Unit | 0.17yr | no data | no data |
1.8yrs
Average Tenure
57yo
Average Age
Experienced Management: AFX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of Supervisory Board | 10.33yrs | €64.00k | no data | |
| Member of the Supervisory Board | 15.75yrs | €56.00k | no data | |
| Supervisory Board Member | 1.33yrs | €23.80k | no data | |
| Employee Representative Member of Supervisory Board | 8.75yrs | €32.00k | no data | |
| Deputy Chairwoman of the Supervisory Board | 2.25yrs | €48.00k | no data | |
| Member of Supervisory Board | 0.75yr | no data | no data |
5.5yrs
Average Tenure
53yo
Average Age
Experienced Board: AFX's board of directors are considered experienced (5.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Carl Zeiss Meditec AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Carl Zeiss Meditec AG
- Ticker: AFX
- Exchange: XTRA
- Founded: 2002
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €8.390b
- Shares outstanding: 89.44m
- Website: https://www.zeiss.com/meditec-ag/home.html
Number of Employees
Location
- Carl Zeiss Meditec AG
- Goschwitzer Strasse 51-52
- Jena
- Thuringia
- 7745
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AFX | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Mar 2000 |
| AFX | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Mar 2000 |
| 0DHC | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Mar 2000 |
| CZMW.F | OTCPK (Pink Sheets LLC) | Yes | Bearer Shares | US | USD | Mar 2000 |
| AFXD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Mar 2000 |
| AFX | SWX (SIX Swiss Exchange) | Yes | Bearer Shares | CH | CHF | Mar 2000 |
| AFX | WBAG (Wiener Boerse AG) | Yes | Bearer Shares | AT | EUR | Mar 2000 |
| AFX | ETLX (Eurotlx) | Yes | Bearer Shares | IT | EUR | Mar 2000 |
| CZMW.Y | OTCPK (Pink Sheets LLC) | UNSPONSORED ADR | US | USD | Oct 2007 | |
| AFXA | DB (Deutsche Boerse AG) | UNSPONSORED ADR | DE | EUR | Oct 2007 |
Biography
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/07 20:50 |
| End of Day Share Price | 2020/07/07 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.